2137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma
OBJECTIVES/SPECIFIC AIMS: In patients with recurrent glioblastoma (GBM) who undergo a second surgery following standard chemoradiotherapy, histopathologic examination of the resected tissue often reveals a combination of viable tumor and treatment-related inflammatory changes. However, it remains un...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2018-06-01
|
| Series: | Journal of Clinical and Translational Science |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2059866118001759/type/journal_article |
| _version_ | 1811156742272188416 |
|---|---|
| author | Robert D. Schwab Stephen Bagley Zev Binder Robert Lustig Donald O’Rourke Steven Brem Arati S. Desai MacLean Nasrallah |
| author_facet | Robert D. Schwab Stephen Bagley Zev Binder Robert Lustig Donald O’Rourke Steven Brem Arati S. Desai MacLean Nasrallah |
| author_sort | Robert D. Schwab |
| collection | DOAJ |
| description | OBJECTIVES/SPECIFIC AIMS: In patients with recurrent glioblastoma (GBM) who undergo a second surgery following standard chemoradiotherapy, histopathologic examination of the resected tissue often reveals a combination of viable tumor and treatment-related inflammatory changes. However, it remains unclear whether the degree of viable tumor Versus “treatment effect” in these specimens impacts prognosis. We sought to determine whether the percentage of viable tumor Versus “treatment effect” in recurrent GBM surgical samples, as assessed by a trained neuropathologist and quantified on a continuous scale, is associated with overall survival. METHODS/STUDY POPULATION: We reviewed the records of 47 patients with histopathologically confirmed GBM who underwent surgical resection as the first therapeutic modality for suspected radiographic progression following standard radiation therapy and temozolomide. The percentage of viable tumor Versus “treatment effect” in each specimen was estimated by one neuropathologist who was blinded to patient outcomes. RESULTS/ANTICIPATED RESULTS: After adjusting for other known prognostic factors in a multivariate Cox proportional hazards model, there was no association between the degree of viable tumor and overall survival (HR 0.83; 95% CI, 0.20–3.4; p=0.20). DISCUSSION/SIGNIFICANCE OF IMPACT: These results suggest that, in patients who undergo resection for recurrent GBM following standard first-line chemoradiotherapy, histopathologic quantification of the degree of viable tumor Versus “treatment effect” present in the surgical specimen has limited prognostic influence and clinical utility. |
| first_indexed | 2024-04-10T04:56:22Z |
| format | Article |
| id | doaj.art-d5fb791f26ca4bae9b539b7ae80dfd0e |
| institution | Directory Open Access Journal |
| issn | 2059-8661 |
| language | English |
| last_indexed | 2024-04-10T04:56:22Z |
| publishDate | 2018-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | Journal of Clinical and Translational Science |
| spelling | doaj.art-d5fb791f26ca4bae9b539b7ae80dfd0e2023-03-09T12:30:15ZengCambridge University PressJournal of Clinical and Translational Science2059-86612018-06-012454510.1017/cts.2018.1752137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastomaRobert D. Schwab0Stephen Bagley1Zev Binder2Robert Lustig3Donald O’Rourke4Steven Brem5Arati S. Desai6MacLean Nasrallah7University of Pennsylvania School of Medicine, Philadelphia, PA, USAAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USAAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USAOBJECTIVES/SPECIFIC AIMS: In patients with recurrent glioblastoma (GBM) who undergo a second surgery following standard chemoradiotherapy, histopathologic examination of the resected tissue often reveals a combination of viable tumor and treatment-related inflammatory changes. However, it remains unclear whether the degree of viable tumor Versus “treatment effect” in these specimens impacts prognosis. We sought to determine whether the percentage of viable tumor Versus “treatment effect” in recurrent GBM surgical samples, as assessed by a trained neuropathologist and quantified on a continuous scale, is associated with overall survival. METHODS/STUDY POPULATION: We reviewed the records of 47 patients with histopathologically confirmed GBM who underwent surgical resection as the first therapeutic modality for suspected radiographic progression following standard radiation therapy and temozolomide. The percentage of viable tumor Versus “treatment effect” in each specimen was estimated by one neuropathologist who was blinded to patient outcomes. RESULTS/ANTICIPATED RESULTS: After adjusting for other known prognostic factors in a multivariate Cox proportional hazards model, there was no association between the degree of viable tumor and overall survival (HR 0.83; 95% CI, 0.20–3.4; p=0.20). DISCUSSION/SIGNIFICANCE OF IMPACT: These results suggest that, in patients who undergo resection for recurrent GBM following standard first-line chemoradiotherapy, histopathologic quantification of the degree of viable tumor Versus “treatment effect” present in the surgical specimen has limited prognostic influence and clinical utility.https://www.cambridge.org/core/product/identifier/S2059866118001759/type/journal_article |
| spellingShingle | Robert D. Schwab Stephen Bagley Zev Binder Robert Lustig Donald O’Rourke Steven Brem Arati S. Desai MacLean Nasrallah 2137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma Journal of Clinical and Translational Science |
| title | 2137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma |
| title_full | 2137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma |
| title_fullStr | 2137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma |
| title_full_unstemmed | 2137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma |
| title_short | 2137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma |
| title_sort | 2137 percentage of viable tumor versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma |
| url | https://www.cambridge.org/core/product/identifier/S2059866118001759/type/journal_article |
| work_keys_str_mv | AT robertdschwab 2137percentageofviabletumorversusradiationtreatmenteffectinsurgicalspecimensisnotassociatedwithoutcomesinrecurrentglioblastoma AT stephenbagley 2137percentageofviabletumorversusradiationtreatmenteffectinsurgicalspecimensisnotassociatedwithoutcomesinrecurrentglioblastoma AT zevbinder 2137percentageofviabletumorversusradiationtreatmenteffectinsurgicalspecimensisnotassociatedwithoutcomesinrecurrentglioblastoma AT robertlustig 2137percentageofviabletumorversusradiationtreatmenteffectinsurgicalspecimensisnotassociatedwithoutcomesinrecurrentglioblastoma AT donaldorourke 2137percentageofviabletumorversusradiationtreatmenteffectinsurgicalspecimensisnotassociatedwithoutcomesinrecurrentglioblastoma AT stevenbrem 2137percentageofviabletumorversusradiationtreatmenteffectinsurgicalspecimensisnotassociatedwithoutcomesinrecurrentglioblastoma AT aratisdesai 2137percentageofviabletumorversusradiationtreatmenteffectinsurgicalspecimensisnotassociatedwithoutcomesinrecurrentglioblastoma AT macleannasrallah 2137percentageofviabletumorversusradiationtreatmenteffectinsurgicalspecimensisnotassociatedwithoutcomesinrecurrentglioblastoma |